A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma

This is a Phase I/II, single-arm, open-label, multicenter clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM). The study aims to evaluate the safety, tolerability, efficacy, cellular kinetics, and immunogenicity of CT0596.

Trial Details

NCT ID
NCT07760454
Phase
PHASE1 / PHASE2
Sponsor
UCARsgen Biotech Limited
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • CT0596
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntarily participate in the trial; fully understand and sign the informed consent form (ICF); willing and able to comply with all trial procedures.
  • Age ≥ 18 years, male or female.
  • Patients with relapsed/refractory multiple myeloma (R/R MM) who have received at least 3 prior lines of therapy, including at least one proteasome …
  • Relapsed/refractory disease defined per IMWG 2016 response criteria,.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →